Schedules of Controlled Substances: Placement of Cipepofol in Schedule IV

On May 29, 2026, the United States Food and Drug Administration (FDA) approved a new drug application for Cypsedo (cipepofol) for induction of general anesthesia in adults undergoing surgery. The Department of Health and Human Services provided the Drug Enforcement Administration (DEA) with a scheduling recommendation to place cipepofol, chemically known as 2-[(1R)-1-cyclopropylethyl]-6- isopropylphenol, in schedule IV of the Controlled Substances Act (CSA). In accordance with the CSA, as amended by the Improving Regulatory Transparency for New Medical Therapies Act, DEA is hereby issuing an interim final rule placing cipepofol in schedule IV of the CSA.